---
title: "NovoCure 2026 年第一季度財報預覽"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/284613352.md"
description: "NovoCure (NVCR) 將於 4 月 30 日公佈其第一季度財報，市場普遍預期每股收益（EPS）為-0.51 美元，同比下降 64.5%；預計收入為 1.6777 億美元，同比增加 8.2%。在過去兩年中，該公司有 63% 的時間超出每股收益和收入預期"
datetime: "2026-04-29T16:31:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284613352.md)
  - [en](https://longbridge.com/en/news/284613352.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284613352.md)
---

# NovoCure 2026 年第一季度財報預覽

NovoCure (NVCR) is scheduled to announce Q1 earnings results on Thursday, April 30th, before market open. The consensus EPS Estimate is -$0.51 (-64.5% Y/Y) and the consensus Revenue Estimate is $167.77M (+8.2% Y/Y). Over the last 2 years, NVCR has beaten EPS estimates 63% of the time and has beaten revenue estimates 63% of the time. Over the last 3...

### 相關股票

- [NVCR.US](https://longbridge.com/zh-HK/quote/NVCR.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)

## 相關資訊與研究

- [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md)
- [儲局會議記錄顯示 大多數官員警告通脹率若持續高於 2%  需考慮加息](https://longbridge.com/zh-HK/news/287171073.md)
- [傳奇生物在 2026 年 ASCO 會議上展示了小細胞肺癌的 LB2102 初步一期數據](https://longbridge.com/zh-HK/news/287272522.md)
- [Pliant Therapeutics 將在 ASCO 會議上公佈 PLN-101095 試驗數據](https://longbridge.com/zh-HK/news/287275498.md)
- [Relay Therapeutics 以每股 12 美元的價格定價 2.75 億美元的股票發行](https://longbridge.com/zh-HK/news/287164486.md)